Navigation Links
Ganeden Biotech Granted 100th Probiotic Patent
Date:10/14/2010

CLEVELAND, Oct. 14 /PRNewswire/ -- Ganeden Biotech, Inc., maker of the patented probiotic strain GanedenBC30®, recently announced the granting of the company's 100th patent, which expands the use and scope of the GanedenBC30® probiotic to help prevent lactic-acid bacteria and to better improve digestive and immune health.  

The 100th patent comes in the wake of Ganeden's latest collaboration with Organic Milling marking a milestone for the company as it continues to develop new product partnerships with some of the world's most innovative food and product manufacturers.  

From Bigelow® Tea and Red Mango to Guernsey Farms Dairy and Agostoni Chocolate, Ganeden's range of products and partnerships is a testament to the versatility and durability of their probiotic strain Bacillus coagulans GBI-30, 6086 branded as GanedenBC30®, which has the unique ability to survive the harsh manufacturing process and still be activated in the body.  This is attributed to the naturally occurring layer of organic material that protects the genetic core of the bacteria throughout the manufacturing and digestion process.

"The 100th patent approval is a true accomplishment for us, as it reflects the extent of our innovation and collaboration since the GanedenBC30® probiotic was first developed and patented just a little over a decade ago," said Sean Farmer, Chief Scientific Officer and co-founder of Ganeden Biotech. Farmer is credited with discovering the GanedenBC30® probiotic and has written each subsequent patent since helping co-found the company in 1997.  "We owe our success to our unrivaled dedication to creativity and perseverance, inherent within each of our partnerships, which have enabled us to provide proven health benefits to millions of consumers via a variety of functional health products."

About Ganeden Biotech

Founded in 1997, Ganeden Biotech, Inc. is based in Cleveland, Ohio, and is the largest seller of over-the-counter probiotics in the U.S. through its Digestive Advantage® and Sustenex® brands. It also licenses its patented probiotic bacteria, GanedenBC30®, for use in commercial food and beverage applications, nutraceuticals and in animal health industries. GanedenBC30® is self-affirmed GRAS (Generally Recognized as Safe) by an independent panel of experts assembled to assess its safety in use as a food ingredient. For more information about licensing opportunities visit ganedenlabs.com and for probiotic supplement information visit digestiveadvantage.com or sustenex.com.


'/>"/>
SOURCE Ganeden Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ganeden Biotech Introduces the First Probiotic Thin Strip
2. Ganeden Biotech Introduces GanPro(TM) Direct-Fed Microbial for Livestock
3. Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology
4. Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener
5. Ganeden Biotech Receives Frost & Sullivan Probiotics Product Innovation Award
6. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
7. Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses
8. Trius to Participate in Antibiotics Panel Discussion at Citis 5th Annual Biotech Day
9. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIREā„¢ Label-Free Detection Technology for Proteomics
10. Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear
11. Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):